Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PFE, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Marstacimab FDA approved Oct 2024 · Hympavzi |
Hemophilia A or B | Phase 3 · NCT07923981 | Recruiting |
| Palbociclib FDA approved Feb 2015 · Ibrance |
HPV-unrelated Head and Neck Squamous Cell Carcinoma | Phase 3 · NCT04966481 | Recruiting |
| Abrocitinib FDA approved Jan 2022 · Cibinqo |
Eczema | Phase 3 · NCT06807268 | Active not recruiting |
| Tucatinib FDA approved Apr 2020 · Tukysa |
Colorectal Neoplasms | Phase 3 · NCT05253651 | Active not recruiting |
| Elranatamab FDA approved Aug 2023 · Elrexfio |
Multiple Myeloma | Phase 3 · NCT06152575 | Recruiting |
| Bortezomib FDA approved May 2022 · Bortezomib |
Multiple Myeloma | Phase 3 · NCT06152575 | Recruiting |
| Etrasimod FDA approved Oct 2023 · Velsipity |
Ulcerative Colitis | Phase 3 · NCT03950232 | Active not recruiting |
| Tisotumab Vedotin FDA approved Sep 2021 · Tivdak |
Vulvar Carcinoma | Phase 2 · NCT07672782 | Not yet recruiting |
| Somatrogon FDA approved Jun 2023 · Ngenla |
Dwarfism, Pituitary | N/A · NCT06587035 | Recruiting |
| Lorlatinib FDA approved Nov 2018 · Lorbrena |
Non-Small-Cell Lung | N/A · NCT07567352 | Active not recruiting |
| Fordadistrogene Movaparvovec | Duchenne Muscular Dystrophy | Phase 3 · NCT05689164 | Terminated |
| Giredestrant | Early Breast Cancer | Phase 3 · NCT07890597 | Not yet recruiting |
| Intra-articular corticosteroid injections | Oligoarthritis, Juvenile | Phase 3 · NCT03728478 | Active not recruiting |
| PG4 Multivalent Vaccine | Pneumococcal Disease | Phase 3 · NCT07794748 | Active not recruiting |
| RSVpreF (Regimen A) | Respiratory Syncytial Virus (RSV) | Phase 3 · NCT07839871 | Recruiting |
| Sigvotatug Vedotin | Non-Small Cell Lung Cancer | Phase 3 · NCT06758401 | Recruiting |
Also used in these trials (approved or third-party drugs, not PFE's own candidates): Pembrolizumab, Leucovorin, Levoleucovorin Calcium, Methotrexate, Oxaliplatin, Pomalidomide, Ritlecitinib, Trastuzumab, Dexamethasone, Cetuximab, Carfilzomib, Elotuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PFE holds $11B in cash and short-term investments (as of Sep 27, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PFE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 521,032,629 | 9.14% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 427,444,872 | 7.50% | 2026-03-31 |
| State Street Corporation | Institution (13F) | 309,573,847 | 5.43% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 137,506,393 | 2.41% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 120,474,634 | 2.11% | 2026-09-30 |
| Fisher Asset Management, LLC | Institution (13F) | 112,118,836 | 1.97% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 96,931,707 | 1.70% | 2026-09-30 |
| Massachusetts Financial Services Co. | Institution (13F) | 64,605,278 | 1.13% | 2026-09-30 |
| Northern Trust Corporation | Institution (13F) | 58,902,014 | 1.03% | 2026-09-30 |
| Pfizer Inc. | 5%+ holder (13D) | 22,032,040 | 0.39% | 2025-11-06 |
| PFIZER INC. (13-5315170) | 5%+ holder (13G) | 1,965,066 | 0.03% | 2026-10-08 |
| Albert Bourla Chairman & CEO, Director · +795,823 options |
Insider | 435,555 | 0.01% | 2026-08-12 |
Share count 5,699,853,733 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-13 filed 2026-11-16 |
BOURLA ALBERT |
Option award (A) | 21 | $28.89 | – |
| 2026-10-30 filed 2026-11-03 |
BOURLA ALBERT |
Option award (A) | 20 | $30.52 | – |
| 2026-10-15 filed 2026-10-16 |
BOURLA ALBERT |
Option award (A) | 20 | $29.44 | – |
| 2026-10-13 filed 2026-10-14 |
BOURLA ALBERT |
Option award (A) | 71 | $28.37 | – |
| 2026-09-30 filed 2026-10-01 |
BOURLA ALBERT |
Option award (A) | 21 | $28.52 | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PFE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →